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We read, “Stratification by quality induces selection bias in a meta-analysis of clinical trials” by Stone 
et al. (1) with interest. We think that the authors have misunderstood the implications of their 
findings, and that their conclusions could mislead authors of systematic reviews. 
 
Stone et al. argue that restriction of meta-analyses to lower risk of bias (higher quality) studies, or 
stratification of meta-analyses according to risk of bias (or quality) leads to selection bias (also 
known as collider bias). Stone et al. repeated the analyses originally reported by Jüni et al. in 1999 
(2) by applying 25 different quality assessment tools to the 17 clinical trials included in the low 
molecular weight heparin meta-analysis originally reported by Nurmohamed et al. (3). They followed 
Jüni et al. in stratifying the trials based on a quality threshold, and finding that the extent of 
discrepancies between intervention effect estimates in trials classified as ‘high’ and ‘low’ quality 
varied according to the quality scale used. They also observed small-study effects – a tendency for 
effects estimated in smaller studies to differ from those estimated in larger studies (4) – more often 
in the lower-quality strata than in the higher-quality strata and attributed these results to the 
stratification (conditioning) on quality. They concluded that discrepancies between the pooled 
estimates in the high- and low-quality trials “are largely because of conditioning on quality, which 
allows precision and effect size to associate within strata by quality” (1). 
 
We believe that Stone et al. have misunderstood the implications of their proposed directed acyclic 
graph (DAG), which is shown in Panel A of Figure 1. Under the assumptions encoded in the DAG, a 
lower quality ranking is a common effect of ‘reasons for biased studies’ and ‘reasons for smaller 
studies’. Stratification on quality ranking will therefore induce an association between study 
precision and study results within quality strata. However, it does not follow that the results within 
strata defined by quality ranking are biased. This would only be the case if results in smaller studies 







Figure 1. Directed acyclic graphs (DAG) depicting assumed relationships between bias and study 
size, as proposed by Stone et al. (1) (Panel A) and with “methodological expertise” as a common 
cause of bias and study size (Panel B), and study size additionally a cause of bias (Panel C). 
 
We believe there are other factors linking study size with risk of bias that Stone et al. have not 
considered. In the more plausible DAG shown in Panel B of Figure 1, greater methodological 
expertise is a common cause of larger study size and lower risk of bias. In this case, conditioning on 
risk of bias will remove the association between biased results and less precise results. Alternatively, 
the DAG in Panel C of Figure 1 below represents a situation in which both risk of bias and study size 
influence results, because smaller studies with statistically non-significant effects are less likely to be 
published. In this case, it would be necessary to condition on both risk of bias and study size.  
 
“Quality” and “risk of bias” are very different concepts, though Stone et al. do not distinguish 
between them clearly. Quality of a trial may include many aspects that are not directly relevant for 
internal validity, such as type of patients included or sample size. Risk of bias, in contrast, focusses 
only on bias understood as internal validity. This is reflected in the fundamental differences between 
“quality scales” and tools to assess “risk of bias”. Neither sample size nor whether a power 
calculation was reported have direct implications for risk of bias in the result an individual study, 
which is why they are not included in either version 1 (5) or 2 (6) of the Cochrane risk of bias tool for 
randomized trials. However, quality scales often include these factors. Stone et al. calculated a 
composite quality score incorporating all items across the 25 scales, one of which posed the 
question, “Was there ≥50 patients per group?” In addition, 11 of the 25 scales included the question, 
“Was there a sample size justification before study and power declared a priori?” In these cases, 






therefore unsurprising that in their case study, Stone et al. found precision and effect size to 
associate within strata by quality.  
 
Assessing risk of bias targets the key question of whether results of studies included in a systematic 
review should be believed, by focusing only on factors likely to influence estimated intervention 
effects. By contrast, quality scales often include items that are not directly related to bias, such as 
“Are both inclusion and exclusion criteria mentioned?”, “Was the therapeutic regimen adequately 
described for the treatment and control group”, and “Were the criteria for measuring outcomes 
clearly described?” (1). For this reason, we discourage the use of quality scales (including the 
composite scale developed by Stone et al.) to appraise included studies, and recommend authors 
focus on risk of bias.  
 
Based on their findings, Stone et al. recommend “The common strategy of assessing the impact of 
quality in meta-analysis by excluding lower or including higher quality studies should be abandoned” 
(1). However, a single old case study is not a good basis for drawing general recommendations for 
conduct of modern systematic reviews. Restriction or stratification according to risk of bias should 
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